MARKET

MRTX

MRTX

Mirati Therapeut
NASDAQ

Real-time Quotes | Nasdaq Last Sale

68.16
+2.27
+3.45%
After Hours: 68.16 0 0.00% 17:00 06/24 EDT
OPEN
66.06
PREV CLOSE
65.89
HIGH
69.36
LOW
64.18
VOLUME
2.35M
TURNOVER
0
52 WEEK HIGH
195.99
52 WEEK LOW
32.96
MARKET CAP
3.78B
P/E (TTM)
-5.7264
1D
5D
1M
3M
1Y
5Y
Here's What Cramer Has To Say About Zuora, Johnson Controls International And More
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Zuora Inc (NYSE: ZUO) is losing money. "It does not fit our criteria of what you should own," he added.
Benzinga · 06/13 12:39
The Zacks Analyst Blog Highlights Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics
Bristol Myers, Turning Point Therapeutics, Regeneron, Novavax, and Mirati Therapeutics are part of Zacks top Analyst Blog.
Zacks · 06/09 14:43
Oppenheimer Adjusts Mirati Therapeutics Price Target to $85 From $105, Maintains Perform Rating
MT Newswires · 06/09 10:20
Biotech Stock Roundup: BMY's Acquisition, REGN to Buy Libtayo & More
Acquisition and other updates from Bristol Myers (BMY) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Zacks · 06/08 17:20
Mirati (MRTX) Up on Positive Data From NSCLC Study on Adagrasib
Mirati (MRTX) gains on positive results from an early stage KRYSTAL-1 study on experimental candidate adagrasib for lung cancer.
Zacks · 06/08 15:45
Did Mirati Therapeutics Just Leapfrog Amgen?
The ability to diagnose cancers with specific genetic alterations offers new hope for developing targeted treatment options for patients. For example, an estimated 22% of all solid-tumor cancers harbor a mutation in the KRAS gene. While there are multipl...
TheStreet.com · 06/07 23:21
Mid-Afternoon Market Update: Dow Rises 100 Points; Kiromic BioPharma Shares Spike Higher
U.S. stocks turned higher toward the end of trading, with the Dow Jones gaining more than 100 points on Tuesday.
Benzinga · 06/07 18:50
CTSO, LIDR and UONE among mid-day movers
Gainers: Aero Clean Technologies (AERC) +49%. Houston American Energy (HUSA) +37%. Jan One (JAN) +37%. Oncorus (ONCR) +41%. Cytosorbents  (CTSO) +33%. Mirati Therapeutics (MRTX) +30%. Omega (OMGA) +27%. Codiak BioSciences (CDAK) +27%. Quantum
Seekingalpha · 06/07 17:10
More
No Data
Learn about the latest financial forecast of MRTX. Analyze the recent business situations of Mirati Therapeut through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

31.25%Strong Buy
50.00%Buy
18.75%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MRTX stock price target is 120.77 with a high estimate of 208.00 and a low estimate of 72.00.
High208.00
Average120.77
Low72.00
Current 68.16
EPS
Actual
Estimate
-2.98-2.23-1.49-0.74
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 321
Institutional Holdings: 67.16M
% Owned: 120.96%
Shares Outstanding: 55.53M
TypeInstitutionsShares
Increased
96
5.43M
New
58
2.10M
Decreased
71
4.48M
Sold Out
67
2.43M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.67%
Pharmaceuticals & Medical Research
+2.48%
Key Executives
Non-Executive Chairman/Lead Director/Independent Director
Faheem Hasnain
President/Founder/Director
Charles Baum
Chief Executive Officer/Director
David Meek
Chief Financial Officer
Laurie Stelzer
Chief Scientific Officer
James Christensen
Other
Benjamin Hickey
Independent Director
Bruce Carter
Independent Director
Julie Cherrington
Independent Director
Aaron Davis
Independent Director
Henry Fuchs
Independent Director
Craig Johnson
Independent Director
Maya Martinez-Davis
Independent Director
Shalini Sharp
No Data
No Data
About MRTX
Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRTX stock methods without spending real money on the virtual paper trading platform.